Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amgen Inc's cholesterol drug succeeds in late-stage trial - Reuters


Thursday, 19 Dec 2013 10:08am EST 

Amgen Inc:Says its experimental cholesterol drug succeeded in reducing the level of bad cholesterol in the blood, compared to a placebo, in a late-stage trial - Reuters.Says the data was consistent with the results from a large mid-stage trial that showed the drug, evolocumab, lowered LDL cholesterol by 52 percent after one year of treatment.Says Evolocumab belongs to class of drugs called PCSK9 inhibitors, which work by blocking a protein that prevents the liver from removing LDL cholesterol from blood.Says the late-stage trial, called Descartes, tested the drug in 901 patients with high levels of bad cholesterol and a range of heart risks. 

Company Quote

139.38
0.69 +0.50%
29 Aug 2014